

INFORMATION DISCLOSURE CITATION (Form PTO 1449 Modified) (Use several sheets if necessary)	ATTY. DOCKET NO. IRVN-007CON2	SERIAL NO. Unassigned
	APPLICANT Gatanaga, et al.	
	FILING DATE Herewith	GROUP Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
K	AA	4,761,371	08/02/1988	Bell et al.			
R	AB	6,083,913	07/04/2000	Dower et al.			


FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AC	(2000) "ENBREL(R) (etanercept) U.S. and European Long-Term Clinical Trial Data Presented at the Annual Meeting of the European League Against Rheumatism." <i>Company News On-Call</i> http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY=/www/story/06-23-2000/0001250565 (23 Jun 2000).
	AD	(2000) "Immunex Reports Second Quarter 2000 Results." <i>Immunex Investor Relations</i> http://www.immunex.com/investor/pressreleases/pr000719.html (19 Jul. 2000).
	AE	Lesslauer, et al., "Recombinant soluble tumor necrosis factor receptotr proteins protect mice form lipopolysaccharide-induced lethality," <i>Eur. J. of Immunol.</i> (1991) Vol. 21:2883-2886.
	AF	Mohler, et al., "Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF Antagonists," <i>J. of Immunol.</i> (Aug. 1, 1993) Vol. 151(3):1548-1561.
	AG	Trehu, et al., "Phase I trail of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera," (Aug 1996) Vol. 2:1341-1351

F:\forms\word 2k forms\form PTO-1449.doc

EXAMINER 	DATE CONSIDERED 7-16-02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	